neo212
neo212: sourced relationships with 1 company · 1 clinical trial tracked.
neo212 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could neo212 → NTHI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Diffuse Astrocytoma, IDH-Mutant | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.
Primary endpoint: Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain
Frequently asked questions
Which companies have sourced relationships with neo212?
neo212 has dated SEC/FDA relationship records for NEONC TECHNOLOGIES HOLDINGS, INC..
How many clinical trials involve neo212?
BioSniper tracks 1 clinical trial involving neo212.